Additional Proxy Soliciting Materials (definitive) (defa14a)
December 21 2021 - 11:15AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the Securities
Exchange
Act of 1934 (Amendment No. )
Filed
by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check
the appropriate box:
☐
|
Preliminary
Proxy Statement
|
|
|
☐
|
Confidential,
For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
☐
|
Definitive
Proxy Statement
|
|
|
☒
|
Definitive
Additional Materials
|
|
|
☐
|
Soliciting
Material Pursuant to §240.14a-12
|
NanoVibronix,
Inc.
(Name
of Registrant as Specified in Its Charter)
(Name
of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
☒
No fee required.
☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
☐ Fee paid previously with preliminary materials:
☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
(1)
|
Amount
previously paid: _________________________________________
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.: _________________________
|
|
|
|
|
(3)
|
Filing
Party: ___________________________________________________
|
|
|
|
|
(4)
|
Date
Filed: ____________________________________________________
|
On
December 21, 2021, NanoVibronix, Inc. (the “Company”) issued a press release (the “Press Release”) announcing
that the Company’s special meeting of stockholders (the “Special Meeting”), originally scheduled for 10:00 a.m. Eastern
time on December 21, 2021, was being adjourned to allow more time for stockholders to vote. A copy of the Press Release is being filed
herewith as definitive additional materials.
NanoVibronix
Adjourns Special Meeting of Stockholders
ELMSFORD,
New York – December 21, 2021 – NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) announced
today that the Company’s Special Meeting of Stockholders, scheduled for 10:00 a.m. Eastern time today, December 21, 2021, has been
adjourned to allow for more time for stockholders to vote due to a lack of quorum. The meeting has been scheduled to reconvene on December
29, 2021 at 10:00 a.m. Eastern time and will be held virtually online at www.virtualshareholdermeeting.com/NAOV2021SM2.
During
the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposal set forth
in the Company’s proxy statement. Proxies previously submitted in respect to the Special Meeting will be voted at the reconvened
meeting unless properly revoked.
The
Company encourages all stockholders who have not yet voted to do so before December 28, 2021 at 11.59 p.m. Eastern time. The stockholders
may vote by internet at www.proxyvote.com, or by telephone at 1-800-690-6903 for stockholders of record and 1-800-454-8683 for beneficial
stockholders, or by returning a properly executed proxy card to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
If
you have any questions, need additional material, or need assistance in voting your shares, please feel free to contact the firm assisting
the Company in the solicitation of proxies, Kingsdale Advisors. Brokers, banks and other nominees may call 416-867-2272. Stockholders
may call toll-free 1-877-657-5856. Or you may contact Kingsdale Advisors by email at contactus@kingsdaleadvisors.com.
About
NanoVibronix
NanoVibronix
Inc. (NASDAQ: NAOV) is a medical device company focusing on noninvasive biological response-activating devices that target wound healing
and pain therapy and can be administered at home, without the assistance of medical professionals. Our WoundShield, PainShield and UroShield
products are backed by novel technology which relates to ultrasound delivery through surface acoustic waves. Additional information about
the Company is available at: www.nanovibronix.com.
Additional
Information and where to find it
The
Company has filed a definitive proxy statement and associated proxy card with the U.S. Securities and Exchange Commission (the “SEC”)
in connection with the solicitation of proxies for the Special Meeting of Stockholders of the Company (the “Special Meeting”)
on December 21, 2021. The Company, its directors, its executive officers and certain other individuals set forth in the definitive proxy
statement will be deemed participants in the solicitation of proxies from shareholders in respect of the Special Meeting. Information
regarding the names of the Company’s directors and executive officers and certain other individuals and their respective interests
in the Company by security holdings or otherwise are set forth in the definitive proxy statement filed with the SEC on November 16, 2021.
BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE
SEC, INCLUDING THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND THE ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. Investors and shareholders can obtain a copy of the documents filed by the Company with the SEC, including the definitive
proxy statement, free of charge by visiting the SEC’s website, www.sec.gov. The Company’s stockholders can also obtain, without
charge, a copy of the definitive proxy statement and other relevant filed documents when available from the Company’s website at
https://ir.nanovibronix.com/sec-filings.
Forward-looking
Statements
This
press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,”
“may,” “will,” “plans,” “expects,” “anticipates,” “projects,”
“predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject
to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) the geographic, social and economic
impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed, (ii) market acceptance
of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial results; (iv)
inability to secure regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much
larger, multinational companies; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capabilities
and reliance on subcontractor assistance; (ix) insufficient or inadequate reimbursements by governmental and/or other third party payers
for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative
or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xii) our reliance on single suppliers
for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiv) our conducting business
in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications
challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions;
and (xv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization
of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including
the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read
these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update
or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor
Contacts:
Brett
Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
(646)
536-7331
SOURCE:
NanoVibronix, Inc.
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024